Release 4 5 Preview #1

This page is part of the FHIR Specification (v4.0.1: R4 - Mixed Normative and STU ) in it's permanent home (it will always be available at this URL). (v4.2.0: R5 Preview #1). The current version which supercedes this version is 5.0.0 . For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4

4.4.1.223 4.4.1.235 Value Set http://hl7.org/fhir/ValueSet/research-study-phase

Biomedical Research and Regulation Work Group   Maturity Level : 1 Draft Use Context : Any

This is a value set defined by the FHIR project.

Summary

Defining URL: http://hl7.org/fhir/ValueSet/research-study-phase
Version: 4.0.1 4.2.0
Name: ResearchStudyPhase
Title: ResearchStudyPhase
Definition:

Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.

Committee: Biomedical Research and Regulation Work Group
OID: 2.16.840.1.113883.4.642.3.821 (for OID based terminology systems)
Source Resource XML / JSON

This value set is used in the following places:

4.4.1.223.1 4.4.1.235.1 Content Logical Definition

This value set includes codes from the following code systems:

 

4.4.1.223.2 4.4.1.235.2 Expansion

This expansion generated 01 Nov 31 Dec 2019

This value set contains 8 concepts

Expansion based on http://terminology.hl7.org/CodeSystem/research-study-phase version 4.0.1 4.2.0

All codes from system http://terminology.hl7.org/CodeSystem/research-study-phase

Code Display Definition
n-a N/A Trials without phases (for example, studies of devices or behavioral interventions).
early-phase-1 Early Phase 1 Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
phase-1 Phase 1 Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
phase-1-phase-2 Phase 1/Phase 2 Trials that are a combination of phases 1 and 2.
phase-2 Phase 2 Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
phase-2-phase-3 Phase 2/Phase 3 Trials that are a combination of phases 2 and 3.
phase-3 Phase 3 Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
phase-4 Phase 4 Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

 

See the full registry of value sets defined as part of FHIR.

Explanation of the columns that may appear on this page:

Lvl A few code lists that FHIR defines are hierarchical - each code is assigned a level. For value sets, levels are mostly used to organize codes for user convenience, but may follow code system hierarchy - see Code System for further information
Source The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance). If the code is in italics, this indicates that the code is not selectable ('Abstract')
Display The display (used in the display element of a Coding ). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code